Royalty Pharma plc (NASDAQ:RPRX) Given Average Rating of “Buy” by Analysts

Royalty Pharma plc (NASDAQ:RPRX) has been assigned a consensus recommendation of “Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $41.60.

Several equities research analysts have commented on the company. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a research note on Friday.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Nissay Asset Management Corp Japan ADV raised its position in shares of Royalty Pharma by 0.7% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company’s stock valued at $1,238,000 after buying an additional 349 shares during the last quarter. Keene & Associates Inc. increased its holdings in Royalty Pharma by 1.9% in the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock valued at $495,000 after acquiring an additional 370 shares during the last quarter. National Bank of Canada FI lifted its stake in Royalty Pharma by 21.8% in the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 371 shares in the last quarter. Blue Trust Inc. lifted its stake in Royalty Pharma by 31.3% in the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 376 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC grew its position in shares of Royalty Pharma by 1.1% during the fourth quarter. Sherbrooke Park Advisers LLC now owns 34,891 shares of the biopharmaceutical company’s stock valued at $890,000 after purchasing an additional 380 shares in the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Trading Down 1.3 %

Royalty Pharma stock traded down $0.42 during mid-day trading on Friday, reaching $31.23. 392,891 shares of the company traded hands, compared to its average volume of 2,913,656. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. Royalty Pharma has a 52-week low of $24.05 and a 52-week high of $34.20. The firm has a market capitalization of $18.00 billion, a price-to-earnings ratio of 21.54, a P/E/G ratio of 2.31 and a beta of 0.47. The firm’s 50 day moving average price is $32.43 and its 200 day moving average price is $28.82.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, analysts anticipate that Royalty Pharma will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were given a dividend of $0.22 per share. The ex-dividend date was Friday, February 21st. This represents a $0.88 annualized dividend and a dividend yield of 2.82%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio (DPR) is currently 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.